SBA Member, 11.06.2018
InSphero extends 3D InSight™ Diabetes Discovery Platform to include ALPCO STELLUX® Chemiluminescent ELISA technology for assessment of pancreatic β-cell function.
Schlieren, Switzerland – InSphero AG, the leading provider of 3D cell-based platforms for preclinical drug safety and efficacy testing, today announced that it is partnering with ALPCO, an established producer of research and clinical immunoassays, to deliver robust and reliable assays certified to work with InSphero 3D InSight™ Islet Microtissues. As a first step in this partnership, the company will now include ALPCO STELLUX® Chemiluminescent insulin and proinsulin ELISAs as part of its 3D InSight™ Diabetes Discovery Platform.
InSphero offers comprehensive solutions and disease models for investigators engaged in type 1 and type 2 diabetes research and drug development. Their 3D InSight™ Diabetes Discovery Platform combines scalable 3D cell-culture technology, functionally-certified pancreatic islet models, optimized culture media, technical protocols, and diverse research services. 3D InSight™ Islet Microtissue models are standardized primary islets that display homogeneous and native-like distribution of endocrine cells as well as uniform, long-term (> 28 days) and robust islet function. The platform is ideal for high-throughput and longitudinal studies of pancreatic islet function, regeneration, and preservation in health and disease.
InSphero Group Head of Islet Solutions Dr. Burcak Yesildag says, “Robust and accurate quantification of insulin secretion from single 3D InSight™ Islet Microtissues requires a highly sensitive method.” InSphero’s Islet platform development team rigorously tested various commercially available insulin ELISAs on the market and ALPCO’s STELLUX® ELISA technology either met or exceeded all their criteria for certification. “We’ve selected ALPCO’s STELLUX® Chemiluminescent ELISA because it combines the high sensitivity and broad dynamic range necessary for our model, and requires only a small sample size, thus preserving precious islet material and enabling multiparametric endpoint analysis,” added Dr. Yesildag.
“Our ongoing partnership with InSphero further exemplifies our dedication to the advancement of metabolic disease research by offering solutions for better insights within early stage development,” says ALPCO President Sean Conley.
Through this partnership agreement with ALPCO, users of InSphero’s 3D InSight™ Diabetes Discovery Platform now receive all the materials they need to conduct experiments to assess β-cell function through a single agreement. InSphero and ALPCO are collaborating to test and certify additional chemiluminescent ELISAs to potentially include in the 3D InSight™ Diabetes Discovery Platform.